agreed. only way over a buck is R/S. Shareholder lose, but Marty will be able to sell shares at much higher price.
And if in January, they are selling shares at 25 cents to fund their lifestyles while promising sales will increase soon. We just need more time and more money for us. then you won't be insulting tapkap but neither will be happy. mgmnt is not looking out for shareholders.
lettucebestupid looking pretty smart right now. a prophet is never accepted in their own chat room. lettuce be kind to those who see management for the self serving shareholder milking scoundrels they are.
Hate to see this back in low 30's
aligning oneself with shareholders is good for shareholders (owners of the company). Hope they make a habit of this. Putting skin in the game every quarter. Bet on your own success.
OK. maybe you are right. No matter how good your product is, if the captain sails it into an iceburg, you sink. We no have good captain.
disagree. technology is there. management has floundered and milked shareholders but they have something very special. will they squander it or parlay it into something special for shareholders?
Each salesperson took one wound each quarter and sold one treatment for that wound. Next quarter, they will try to treat two wounds and Martin can announce sales have doubled. By leading his team to DOUBLING sales, he will undoubtedly expect a bonus and a raise.
Some builders have a plan, anticipate, prepare, .... Some builders always seem to have excuses and are constantly caught by surprise.
Be a pal to martin and he puts you on the board. Just have to be able to milk shareholders without being guilty or afraid of karma.
I thought it was Marty or Jason. The anger is evident. Either defensive or maybe a disgruntled shareholder who trusted Martin completely.
each and every executive buying shares on open market tomorrow would do a lot for damage control.
During the first half of the year, we set into motion a series of initiatives aimed at positioning Cytomedix for long-term growth in the multi-billion dollar U.S. wound care market. We believe that our lead product, AutoloGel™, presents a compelling value proposition for patients, clinicians and payors alike. The changing reimbursement landscape clearly favors highly-efficacious and high value wound care products such as ours,” said Martin Rosendale, Chief Executive Officer of Cytomedix. “Since the beginning of the year, we strengthened our executive team with key appointments in commercialization, reimbursement, sales and marketing which greatly enhance our go-to-market capabilities as we launch AutoloGel™ under the Coverage with Evidence Development (CED) program later this year.”
“Our top priority in the near-term remains the successful commercialization and ramp of AutoloGel™, which we believe will be the foundation for long-term, sustainable growth and profitability.”
Steven Shallcross, Chief Financial Officer of Cytomedix, added, “During the second quarter, we significantly strengthened our balance sheet with the closing of the second tranche of the Deerfield convertible debt financing. Additionally, we completed our strategic realignment by discontinuing our ALD-401 Bright Cell development program and closing the Durham facility. This strategic realignment is expected to yield annual cost savings of approximately $4 million. It will also allow us to dedicate additional resources to the commercialization of AutoloGel and our future growth in the wound care market.”
BUT THEY COULD HAVE said:
We diluted shareholders to pad our wallets. We hired additional executives because we can't seem to get it done. We failed Bright Cell so we are now a one trick pony. We aren't getting much of anything for Angel so it really is all about AutoGel and months later, all we could sell was $100,000. Not even enough to cover my salary. Any questions Jason?
Second Quarter 2014 Financial Summary
Total revenues were $2.3 million, compared with $2.4 million in the second quarter of 2013
AutoloGel™ sales increased 9.1% year-over-year to $120,000
Net loss of $11.3 million, or $0.09 per share compared with a net loss of $5.0 million, or $0.05 per share in the prior year
Second quarter net loss included non-cash impairment charges totaling $4.7 million relating to in-process research and development and trademarks following the discontinuation of ALD-401
Cash and cash equivalents of approximately $25.0 million as of June 30, 2014
lucky to stay above 29 cents on Friday.
Put some skin in the game. Stand alongside shareholders
Why no insiders buying if CMXI so undervalued. This big of drop with heavy volume would be great time for insiders to put up some of their own money and buy some of their company. Show some faith in their future. Skin in the game. INstead of getting bonuses and options in the money. Stand beside shareholders and treat them as though you care.
I'd think seeking alpha would be embarrassed to have Jason pumping stocks without really knowing anything. He tweets breakout when stock goes up for a few hours ... what does he say today with heavy vol and down 10%. Does he tweet anything?
Don't forget the "we will have to sell more shares so we can expand our sales force and pay ourselves what we feel we deserve and eventually we will have to do a reverse split. Shareholders shouldn't mind because Jason says we are undervalued". Hang in there with Martin.